{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The highest dose level that produces 1/6 dose-limiting toxicities (DLTs) in Cycle #1 will be the maximum tolerated dose (MTD). The RP2D of ixazomib and pomalidomide will generally be the MTD, but it may be less than the MTD based on a review of available data/cumulative toxicities from phase I.","groups":[{"description":"Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level #2 (4mg MLN9708)"}],"paramType":"NUMBER","populationDescription":"6 patients treated at dose level #2 in Phase I are evaluable for dose limiting toxicity.","reportingStatus":"POSTED","timeFrame":"From the initial treatment to Day 28 (Cycle #1)","title":"Maximum Tolerated Dose (MTD) of MLN9708 (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}